FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 FDA Approves Nirogacestat for Desmoid Tumours December 7, 2023 Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age October 26, 2020 Opinion: ‘Medical research charities are falling through the cracks of COVID-19... June 16, 2020 Load more HOT NEWS Gut Microbes May Influence How Well Radiation Therapy Works against Cancer News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... Making real change: 4 ways we’ve influenced cancer policy Cancer in My Community: Bringing Palliative Care to People With Cancer...
